Diamyd close to important milestone

Diamyd Medical announces today that 90 percent of the total 320 children and adolescents with type 1 diabetes due to participate in the company’s European Phase III study with the diabetes vaccine Diamyd® have now been included and have received injections of Diamyd® or placebo. The company expects all participants to have been included in the study by November 2009.Diamyd Medical is conducting a global Phase III program with the diabetes vaccine Diamyd® comprising a study in nine countries in Europe and a study in the US. In each study 320 children and adolescents aged 10-20 newly